Anti-β2-glycoprotein I antibodies and the antiphospholipid syndrome

被引：10

作者：

Li, Z ^{[1
]}

Krilis, SA

机构：

[1] Univ New S Wales, St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia

[2] Univ New S Wales, St George Hosp, Dept Med, Kogarah, NSW 2217, Australia

来源：

AUTOIMMUNITY REVIEWS | 2003年 / 2卷 / 05期

关键词：

antiphospholipid syndrome; anti-cardiolipin antibodies; anti-phospholipid antibodies; beta(2)-glycoprotein I; anti beta(2)-glycoprotein I antibody;

D O I：

10.1016/S1568-9972(03)00015-6

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The mechanism of antiphospholipid syndrome (APS) development is still not completely understood. Accumulating evidence indicates that beta(2)-glycoprotein I (beta(2)GPI), is the major target antigen for antiphospolipid (aPL) antibodies, which play a crucial role in the pathogenesis of this autoimmune condition. Knowledge about the molecular structure, biological characteristics and function of beta(2) GPI has been expanding in recent years. In this review, we have focused on some recent important findings on beta(2) GPI and anti-beta(2)GPI antibodies in patients and animal models with APS. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：229 / 234

页数：6